Itracure 200 Capsule contains Itraconazole 200 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various systemic and superficial fungal infections, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for ergosterol synthesis, a critical component of fungal cell membranes. This inhibition disrupts membrane integrity, leading to fungal cell death. Itracure 200 is administered orally and exhibits good bioavailability, with absorption enhanced when taken with food. It undergoes extensive hepatic metabolism primarily via the CYP3A4 pathway and has a half-life of approximately 24 to 42 hours, allowing for once or twice daily dosing depending on the indication. Caution is advised in patients with hepatic impairment, congestive heart failure, or those receiving concomitant medications metabolized by CYP3A4 due to potential drug interactions. Common adverse effects include gastrointestinal disturbances, headache, and rash. Liver function tests should be monitored periodically during therapy. Itracure 200 Capsule should be prescribed and used under medical supervision to ensure efficacy and safety.